Skye Bioscience (SKYE) CEO on Drug Development

Skye Bioscience (SKYE) focuses on developing proprietary molecules to treat diseases involving inflammatory, fibrotic, and metabolic conditions. CEO Punit Dhillon joins Nicole Petallides to discuss the latest in drug development. He also talks about the competition in the obesity space. Tune in to find out more about the stock market today.

Trading 360

14 May 2024

SHARE

Schwab Network's Newsletters

Daily insights for every investor